Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-14
2006-11-14
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S274000, C514S456000, C514S533000, C514S283000
Reexamination Certificate
active
07135481
ABSTRACT:
Methods of treating a solid tumor are disclosed comprising administering amonafide in combination with an antiproliferative agent.
REFERENCES:
patent: 5420137 (1995-05-01), Brana et al.
patent: 6630173 (2003-10-01), Brown
patent: 6734178 (2004-05-01), Brown
patent: 2002/0123469 (2002-09-01), Brown
patent: 2003/0176496 (2003-09-01), Medford et al.
patent: 2004/0047918 (2004-03-01), Brown
patent: 2004/0077629 (2004-04-01), Brown
patent: 2004/0082565 (2004-04-01), Brown
patent: 2004/0082788 (2004-04-01), Brown
patent: 2004/0185117 (2004-09-01), Brown
patent: 2005/0170015 (2005-08-01), Brown
patent: 2005/0192312 (2005-09-01), Brown
patent: 2 673 944 (1992-09-01), None
patent: WO 01/68098 (2001-09-01), None
Malonne et al., Anti-Cancer Drugs, 8/9 (811-822) (1997) (abstract).
Scheithauer et al., Breast Cancer Research and Treatment, 20:63-67 (1991).
Twentyman, P.R. et al., Journal of the National Cancer Institute, 64(3), (Mar. 1980), 595-604.
Abbott, B.J., et al., “Screening Data from the Cancer Chemotherapy National Service Center Screening Laboratories. XXXVI. Plant Extracts,”Cancer Res. Supp., 26(9):1131-1136 (Sep. 1966).
Ajani, J.A., et al., “In vitroactivity of amonafide against primary human tumors compared with the activity of standard agents,”Invest. New Drugs, 6(2):79-85 (Jun. 1988).
Asbury, R.F., et al., “A Gynecological Oncology Group phase II study of amonafide (NSC #308847) in sqamous cell carcinoma of the cervix,”Am. J. Clin. Oncol., 17(2):125-128 (Apr. 1994).
Bernges, F., et al., “Combination effects of poly(ADP-ribose) polymerase inhibitors and DNA-damaging agents in ovarian tumor cell lines—with special reference to cisplatin,”J. Cancer Res. Clin. Oncol., 122(11):665-670 (1996).
Cobb, P.W., et al., “Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units,”J. Natl Cancer Inst., 86(19):1462-1465 (Oct. 1994).
Costanza, M.E., et al., “Amonafide: An Active Agent in the Treatment of Previously Untreated Advanced Breast Cancer—A Cancer and Leukemia Group B Study (CALGB 8642),”Clin. Cancer Res. 1(7):699-704 (Jul. 1995).
Costanza, M.E., et al., “Safety and efficacy of using a single agent or a phase II agent before instituting standard combination chemotherapy in previously untreated metastatic breast cancer patients: report of a randomized study—Cancer and Leukemia Group B 8642,”J. Clin. Oncol., 17(5):1397-1406 (May 1999).
Evans, W.K., et al., “Phase II study of amonafide: results of treatment and lessons learned from the study of an investigational agent in previously untreated patients with extensive small-cell lung cancer,”J. Clin. Oncol., 8(3):390-395 (Mar. 1990).
Gallion, H.H., et al., “Phase II trial of amonafide in previously treated patients with advanced ovarian cancer: a Southwest Oncology Group study,”Gynecol. Oncol., 46(2);230-232 (Aug. 1992).
Günther, A., et al., “Differential Expression of Intermediate-Filament Proteins in Murine Sarcoma 180 Ascites or Solid Tumor,”Cancer Res., 44(6):2590-2594 (Jun. 1984).
Hayes, D.F., et al., “Treatment of metastatic breast cancer: present and future prospects,”Semin. Oncol., 22(2 Supp. 5):5-19; disc. 19-21 (Apr. 1995).
Innocenti, F., “Pharmacogenetics: a tool for individualizing antineoplastic therapy,”Clin. Pharmacokinet., 39(5):315-325 (Nov. 2000).
Jin, X., et al., “Cisplatin combination therapy of murine S180,”Shanghai Yike Daxue Xeubao, 16(1):50-54 (1989), Caplus Accession No. 1989:225174, (Abstract Only).
Laster, W.R., et al., “Therapeutic synergism (TS) of homoharringtonine (H) plus 5-fluorouracil (FU) against leukemia P388 (P388/0) and ARA-C-resistant P388 (P388/ARA-C),”Proc. Am. Assn. Cancer Res., 23:786 (1982), Embase Accession No. 82182588, (Abstract only).
Magnusson, K., et al., “Is conversion of solid into more anoxic ascites tumors associated with p53 inactivation?,”Oncogene, 17(5):2333-2337 (Nov. 1998).
Malonne, H., et al., “DNA topoisomerase targeting drugs: Mechanisms of action and perspectives,”Anti-Cancer Drugs, 8(9):811-822 (1997) (Abstract only).
Pérez, J.M., et al., “Combined effect of platination and intercalation upon DNA binding of novel cytotoxic Pt-bis(naphthalimide) complexes,”J. Med. Chem., 42(26):5482-5486 (Dec. 1999).
Powell, R.G., “Antitumor alkaloids forCephalotaxus harringtonia: structure and activity,”J. Pharm. Sci. 61(8):1227-1230 (Aug. 1972).
Provencher, D., et al., “Discordance in p53 Mutations When Comparing Ascites and Solid Tumors from Patients with Serious Ovarian Cancer,”Tumor Biol., 18(3):167-174 (1997).
Savage, K.E., et al., “Effect of tunicamycin, an inhibitor of protein glycosylation, on division of tumor cellsin vitro,” 64:295-306 (Nov. 1983).
Takano, I., et al., “Ester-typeCephalotaxus alkaloids fromCephalotaxus harringtoniavar.drupacea,” Phytochemistry, 44(4):735-738 (1997).
Takano, I., et al., “Ester-typeCephalotaxusalkaloids fromCephalotaxus harringtoniavar.drupacea,” Phytochemistry, 44(4):735-738 (1997).
Visani, G., et al., “Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside onin vitrogrowth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors,”Leukemia, 11:624-628 (May 1997).
Wong, K., et al., “Management of metastatic breast cancer,”World J. Surg., 18(1):98-111 (Jan.-Feb. 1994).
Yuzhu, Z., et al., “Homoharringtonine, cytarabine and aclarubicin (HAA) combination chemotherapy for acute myeloid leukemia (AML),”Chin. J. Clin. Oncol., 25(10):758-759 (1998), Embase Accession No. 1998384948, (Abstract only).
Zhang, S.D., et al., “Inhibitory effects of homoharringtonine and hydroxycamptothecin in combination with other agents on cancer cell growth,”Asia Pac. J. Pharmacol., 7:191-195 (1992).
ChemGenex Pharmaceuticals, Inc.
Dorsey & Whitney LLP
Spivack Phyllis G.
Trecartin Richard F.
LandOfFree
Naphthalimide compositions and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Naphthalimide compositions and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Naphthalimide compositions and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3621117